실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

9,268+프로그램
35+FDA 승인
4,079+모집 중
ADC 1068·Antibody 5456·CGT 2744차세대 추천 →·Data Tier →
9268프로그램35FDA 승인
4오늘 방문
572누적 방문
8122갱신 대기S–CData TierS/A/B차세대1068HER2 breast5456Antibody2744CGT→Psoriasis→NSCLC35FDA 승인
피드Data Tier차세대

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · Ebglyss혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

최근 활동

RSS →

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
다음 갱신 D-12 · 마지막 7월 13일
CGTBiologicstaleUTC Therapeutics Inc.Phase 1

anti-mesothelin CAR-T cells (anti-mesothelin CAR-T cells)

Solid Tumor, Adult · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 23상태 ACTIVE
AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5
효능 ORR 33.3%임상시험 23상태 DISCONTINUED
ADCBiologicstaleAlliance Foundation Trials, LLC.Phase 2

Giredestrant (Giredestrant)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 50%임상시험 23상태 RECRUITING
AntibodystaleAstraZenecaPhase 3

zolbetuximab (zolbetuximab)

Gastric Cancer; Gastroesophageal Junction Adenocarcinoma · Locally Advanced Unresectable Gastroesop

#LocallyAdvancedUnresectableGastr#Antibody#Phase3#항체#면역항체+4
효능 ORR 48.1%임상시험 23상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Nemtabrutinib (Nemtabrutinib)

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0.0%임상시험 23상태 RECRUITING
AntibodystaleRegeneronPhase 2

Cemiplimab plus REGN3767 (Cemiplimab plus REGN3767)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 23상태 RECRUITING
ADCBiologicstaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 27.8%임상시험 23상태 ACTIVE
AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 76%임상시험 23상태 DISCONTINUED
ADCBiologicstaleShanghai Henlius BiotechPhase 3

TCbHP (TCbHP)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 23상태 RECRUITING
ADCBiologicstaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 1%임상시험 23상태 RECRUITING
AntibodystaleDiwakar DavarPhase 2

Domvanalimab (Domvanalimab)

Melanoma · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-3 Lyo-DP (HER3-DXd, HER3-DXd (CTM-3 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 2

LCAR-B38M CAR-T Cell (LCAR-B38M CAR-T Cell)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 96.6%임상시험 22상태 DISCONTINUED
AntibodystaleRegeneron PharmaceuticalsPhase 2

Linvoseltamab (Linvoseltamab)

Food Allergy · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Monalizumab (Monalizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 23.9%임상시험 22상태 RECRUITING
ADCBiologicstaleInstitut du Cancer de Montpelli…Phase 1

TDM1 (TDM1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 9.3%임상시험 22상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

HER3-DXd (HER3-DXd)

Carcinoma, Non-Small-Cell Lung · HER3

#HER3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 56%임상시험 22상태 RECRUITING
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab [KEYTRUDA®])

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · Metastatic Cancer

#MetastaticCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 40%임상시험 22상태 DISCONTINUED
ADCBiologicstaleHansoh BioMedical R&D CompanyPhase 2

HS-20093 (HS-20093)

Advanced Solid Tumor · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 22상태 RECRUITING
AntibodystaleJanssenApproved

daratumumab (Darzalex, Daratumumab and Hyaluronidase-fihj)

Multiple Myeloma; Newly Diagnosed Multiple Myeloma · Amyloid Light-chain Amyloidosis

#AmyloidLight-chainAmyloidosis#Antibody#Approved#항체#면역항체+4
효능 ORR 0.0%임상시험 22상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 1

MEDI5752 (MEDI5752)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 22상태 RECRUITING
AntibodyJanssenPreclinical

Anti TNF therapy including infliximab (Anti TNF therapy including infliximab)

Crohn's Disease; Ulcerative Colitis · Crohn's Disease

#CrohnsDisease#Antibody#Preclinical#항체#면역항체+4
임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-1 Lyo-DP (HER3-DXd, HER3-DXd (CTM-1 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleDualityBio Inc.Phase 2

BNT327 (BNT327)

Solid Tumors · Solid Tumors

#SolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 21상태 RECRUITING
CGTBiologicstaleLion TCR Pte. Ltd.Phase 1

TCR redirected T cells (TCR redirected T cells)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#세포유전치료#CAR-T+2
효능 ORR 15%임상시험 21상태 ACTIVE

31 / 167 페이지

← 이전다음 →
전체 9,268개 프로그램 보기